Mark Mujer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mark Mujer has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Manoj Ponadka Rai
Michigan State University
4 shared publications - Yehia Saleh
Yehia Saleh, University of Iowa, Iowa, USA
3 shared publications Abdullah Al‐Abcha
Department of Medicine Michigan State University East Lansing Michigan
2 shared publicationsKhader Herzallah
Department of Medicine Michigan State University East Lansing Michigan
2 shared publicationsManel Boumegouas
Department of Internal Medicine, Michigan State University, East Lansing, Michigan
2 shared publicationsSamanjit Kaur Kandola
Michigan State University, East Lansing, Michigan, USA
2 shared publications
Latest Publications
- Open Access
- 5 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (Supplement) , 20
Antithrombin Supplementation in Adults with Acute Lymphoblastic Leukemia (ALL) Following Asparaginase Therapy: A Meta-Analysis
Background: Aspagarinase is a fundamental component for the treatment of patients with acute lymphoblastic leukemia (ALL). Venous thromboembolism (VTE) is a known complication of asparaginase therapy during treatment for ALL. This is attributed to the depletion of anticoagulants, particularly acquired antithrombin deficiency following asparaginase administration. The incidence of thrombosis following asparaginase is more prevalent in adults versus children and is estimated to be around 5-35 % and 2.4-8% respectively. Multiple studies have investigated the efficacy and safety of antithrombin supplementation. The recent THROMBOTECT study showed that prophylactic use of antithrombin (AT) or low molecular weight heparin (LMWH) is associated with significant risk reduction of thromboembolism in children and adolescents during induction chemotherapy of ALL. Our study sought to review the cohort studies comparing VTE in adults with and without AT supplementation in ALL receiving asparaginase and specifically evaluate the efficacy of this strategy. Methods: We performed a systematic search using PubMed, Google Scholar, EMBASE, SCOPUS and ClinicalTrials.gov without language restriction up until July 20th 2020. A random effects model was utilized to calculate risk ratio (RR) and mean difference (MD) with 95% confidence interval (CI). Results: Eight studies fulfilled our inclusion criteria (table 1) and were retrospective cohort studies. In adult patients, with ALL treated with asparaginase, the incidence of VTE was significantly lower in those who received AT [RR=0.46 (95 % CI= 0.31-0.70; p= 0.0002) (figure 1.1). The threshold for AT supplementation was 60-70% in most of the studies, with the exception of two studies where the threshold was 50%. Conclusion: In our meta-analysis of the current available data,Antithrombin supplementation in adults with ALL receiving asparaginase was associated with a significant decrease in the risk of venous thromboembolism compared to those who didn't receive thromboprophylaxis. Our data suggest the benefit of antithrombin supplementation in adults with ALL treated with asparaginase. We suggest that this strategy be implemented in a large prospective clinical trial to further confirm the benefit of this intervention. Disclosures: No relevant conflicts of interest to declare.
- 5 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (Supplement) , 20
Open AccessAntithrombin Supplementation in Adults with Acute Lymphoblastic Leukemia (ALL) Following Asparaginase Therapy: A Meta-Analysis
Background: Aspagarinase is a fundamental component for the treatment of patients with acute lymphoblastic leukemia (ALL). Venous thromboembolism (VTE) is a known complication of asparaginase therapy during treatment for ALL. This is attributed to the depletion of anticoagulants, particularly acquired antithrombin deficiency following asparaginase administration. The incidence of thrombosis following asparaginase is more prevalent in adults versus children and is estimated to be around 5-35 % and 2.4-8% respectively. Multiple studies have investigated the efficacy and safety of antithrombin supplementation. The recent THROMBOTECT study showed that prophylactic use of antithrombin (AT) or low molecular weight heparin (LMWH) is associated with significant risk reduction of thromboembolism in children and adolescents during induction chemotherapy of ALL. Our study sought to review the cohort studies comparing VTE in adults with and without AT supplementation in ALL receiving asparaginase and specifically evaluate the efficacy of this strategy. Methods: We performed a systematic search using PubMed, Google Scholar, EMBASE, SCOPUS and ClinicalTrials.gov without language restriction up until July 20th 2020. A random effects model was utilized to calculate risk ratio (RR) and mean difference (MD) with 95% confidence interval (CI). Results: Eight studies fulfilled our inclusion criteria (table 1) and were retrospective cohort studies. In adult patients, with ALL treated with asparaginase, the incidence of VTE was significantly lower in those who received AT [RR=0.46 (95 % CI= 0.31-0.70; p= 0.0002) (figure 1.1). The threshold for AT supplementation was 60-70% in most of the studies, with the exception of two studies where the threshold was 50%. Conclusion: In our meta-analysis of the current available data,Antithrombin supplementation in adults with ALL receiving asparaginase was associated with a significant decrease in the risk of venous thromboembolism compared to those who didn't receive thromboprophylaxis. Our data suggest the benefit of antithrombin supplementation in adults with ALL treated with asparaginase. We suggest that this strategy be implemented in a large prospective clinical trial to further confirm the benefit of this intervention. Disclosures: No relevant conflicts of interest to declare.
- 8 July 2020
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 43 (8) , 856-865
A comparison of figure‐of‐8‐suture versus manual compression for venous access closure after cardiac procedures: An updated meta‐analysis
Background Manual compression (MC) is the current standard to achieve postprocedural hemostasis in patients who need venous vascular access closure after cardiovascular procedures. Figure‐of‐8 (F8) suture for venous access closure has been reported to be a safe and efficacious alternative to MC. Methods A systematic search was done using PubMed, Google Scholar, EMBASE, SCOPUS, and ClinicalTrials.gov without language restriction up until April 15, 2020 for studies comparing F8 suture versus MC. Risk ratio (RR) and mean difference (MD) with 95% confidence interval (CI) were calculated using a random effects model. Results Time to achieve hemostasis was significantly reduced in the F8 arm [MD −21.04 min (95% CI: −35.66 to −6.42; P = .005)]. Access site bleeding was significantly lower in the F8 group [RR 0.35 (95% CI: 0.18 to 0.66; P = .001)] along with a lower incidence of hematoma formation [RR 0.42 (95% CI: 0.26 to 0.67; P = .0003)]. There was no significant difference in rates of fistula or pseudoaneurysm formation between the two groups. Overall access site complications were lower in the F8 arm [RR 0.38 (95% CI: 0.26 to 0.55; P < .00001)] and the effect was more pronounced for sheaths ≥10 Fr [RR 0.33 (95% CI: 0.18 to 0.60; P = .0003)]. There was lower postprocedural protamine use in the F8 group [RR 0.07 (95% CI: 0.01 to 0.36; P = .001)]. Conclusion For large‐bore venous access closure, the F8 suture results in a shortened time to achieve hemostasis along with a lower overall risk of access site complications and postprocedural protamine use.
- 8 July 2020
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 43 (8) , 856-865
A comparison of figure‐of‐8‐suture versus manual compression for venous access closure after cardiac procedures: An updated meta‐analysis
Background Manual compression (MC) is the current standard to achieve postprocedural hemostasis in patients who need venous vascular access closure after cardiovascular procedures. Figure‐of‐8 (F8) suture for venous access closure has been reported to be a safe and efficacious alternative to MC. Methods A systematic search was done using PubMed, Google Scholar, EMBASE, SCOPUS, and ClinicalTrials.gov without language restriction up until April 15, 2020 for studies comparing F8 suture versus MC. Risk ratio (RR) and mean difference (MD) with 95% confidence interval (CI) were calculated using a random effects model. Results Time to achieve hemostasis was significantly reduced in the F8 arm [MD −21.04 min (95% CI: −35.66 to −6.42; P = .005)]. Access site bleeding was significantly lower in the F8 group [RR 0.35 (95% CI: 0.18 to 0.66; P = .001)] along with a lower incidence of hematoma formation [RR 0.42 (95% CI: 0.26 to 0.67; P = .0003)]. There was no significant difference in rates of fistula or pseudoaneurysm formation between the two groups. Overall access site complications were lower in the F8 arm [RR 0.38 (95% CI: 0.26 to 0.55; P < .00001)] and the effect was more pronounced for sheaths ≥10 Fr [RR 0.33 (95% CI: 0.18 to 0.60; P = .0003)]. There was lower postprocedural protamine use in the F8 group [RR 0.07 (95% CI: 0.01 to 0.36; P = .001)]. Conclusion For large‐bore venous access closure, the F8 suture results in a shortened time to achieve hemostasis along with a lower overall risk of access site complications and postprocedural protamine use.
- 8 July 2020
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 43 (8) , 866-874
Effect of combined renal denervation and pulmonary vein isolation in atrial fibrillation recurrence in hypertensive patients: A meta‐analysis
Background: Atrial Fibrillation (AF) is the most common cardiac arrhythmia and hypertension is the most common risk factor associated with AF. The addition of renal sympathetic nerve denervation (RSDN) to pulmonary vein isolation (PVI) in AF patients with hypertension has been reported to improve clinical outcomes.Methods: A systematic search was performed for studies on patients with AF and hypertension that compared RSDN with PVI versus PVI‐alone. Risk ratio (RR) for categorical variables and mean difference (MD) for continuous variables with 95% confidence intervals were used.Results: Seven studies with a total of 734 patients were included. A total of 340 patients were in the RSDN + PVI group (46.32%) and 394 (53.67%) in the PVI group. A total of 608 patients had paroxysmal AF (83%) while 126 patients had persistent AF (17%). At 12 months follow‐up, RSDN + PVI decreased the overall risk of AF recurrence in hypertensive patients with RR 0.60 [95% CI 0.50‐0.72, P < .00001]. A subgroup analysis performed in patients with drug‐resistant hypertension showed a similar reduction in AF recurrence with RR 0.61 [95% CI: 0.47‐0.79, P = .0002). Procedure duration MD + 28.05 min [95% CI: 18.88‐37.23, P < .00001] and fluoroscopy duration MD + 5.59 min [95% CI: 3.31‐8.19, P < .00001] were significantly longer with the RSDN + PVI group. There was no significant difference in complications between the two groups.Conclusion: The addition of RSDN to PVI in patients with AF and hypertension appears safe and decreases AF recurrence. Similar results were observed in patients with drug‐resistant hypertension. Larger trials are needed to confirm these results.
- 8 July 2020
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 43 (8) , 866-874
Effect of combined renal denervation and pulmonary vein isolation in atrial fibrillation recurrence in hypertensive patients: A meta‐analysis
Background: Atrial Fibrillation (AF) is the most common cardiac arrhythmia and hypertension is the most common risk factor associated with AF. The addition of renal sympathetic nerve denervation (RSDN) to pulmonary vein isolation (PVI) in AF patients with hypertension has been reported to improve clinical outcomes.Methods: A systematic search was performed for studies on patients with AF and hypertension that compared RSDN with PVI versus PVI‐alone. Risk ratio (RR) for categorical variables and mean difference (MD) for continuous variables with 95% confidence intervals were used.Results: Seven studies with a total of 734 patients were included. A total of 340 patients were in the RSDN + PVI group (46.32%) and 394 (53.67%) in the PVI group. A total of 608 patients had paroxysmal AF (83%) while 126 patients had persistent AF (17%). At 12 months follow‐up, RSDN + PVI decreased the overall risk of AF recurrence in hypertensive patients with RR 0.60 [95% CI 0.50‐0.72, P < .00001]. A subgroup analysis performed in patients with drug‐resistant hypertension showed a similar reduction in AF recurrence with RR 0.61 [95% CI: 0.47‐0.79, P = .0002). Procedure duration MD + 28.05 min [95% CI: 18.88‐37.23, P < .00001] and fluoroscopy duration MD + 5.59 min [95% CI: 3.31‐8.19, P < .00001] were significantly longer with the RSDN + PVI group. There was no significant difference in complications between the two groups.Conclusion: The addition of RSDN to PVI in patients with AF and hypertension appears safe and decreases AF recurrence. Similar results were observed in patients with drug‐resistant hypertension. Larger trials are needed to confirm these results.
- 5 May 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (5) , e229698
Rarecase of biventricular thrombi complicating pulmonary embolism
A 70-year-old man with a history of chronic lymphocytic leukaemia (CLL) in remission, hypertension, dyslipidaemia and active smoking presented with a 2-week history of non-productive cough, progressive shortness of breath and right lower extremity swelling. On presentation, the patient was
- 5 May 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (5) , e229698
Rarecase of biventricular thrombi complicating pulmonary embolism
A 70-year-old man with a history of chronic lymphocytic leukaemia (CLL) in remission, hypertension, dyslipidaemia and active smoking presented with a 2-week history of non-productive cough, progressive shortness of breath and right lower extremity swelling. On presentation, the patient was
- 22 February 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (2) , e229184
Pulmonary embolism with right ventricular thrombus: a management dilemma
A woman in her 80s with Alzheimer’s disease presented with dyspnoea and chest pain. The patient had a heart rate of 109, respiratory rate of 24 and was hypoxic, needing 4 L of oxygen supplementation. Blood pressure was at 142/78 which was her baseline. Physical examination showed an anxious
- 22 February 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (2) , e229184
Pulmonary embolism with right ventricular thrombus: a management dilemma
A woman in her 80s with Alzheimer’s disease presented with dyspnoea and chest pain. The patient had a heart rate of 109, respiratory rate of 24 and was hypoxic, needing 4 L of oxygen supplementation. Blood pressure was at 142/78 which was her baseline. Physical examination showed an anxious
- 21 January 2019
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 95 (1126) , 420-424
Overutilisation of imaging studies for diagnosis of pulmonary embolism: are we following the guidelines?
Objective To evaluate if imaging studies such as CT pulmonary angiography (CTPA) or ventilation–perfusion (V/Q) scan are ordered according to the current guidelines for the diagnosis of pulmonary embolism (PE). Methods We performed a retrospective observational cohort study in all adult patients who presented to the Sparrow Hospital Emergency Department from January 2014 to December 2016 and underwent CTPA or V/Q scan. We calculated the Wells’ score retrospectively, and d-dimer values were used to determine if the imaging study was justified. Results A total of 8449 patients underwent CTPA (93%) or V/Q scan (7%), among which 142 (0.2%) patients were diagnosed with PE. The Wells’ criteria showed low probabilities for PE in 96 % and intermediate or high probabilities in 4 % of total patients. Modified Wells’ criteria demonstrated PE unlikely in 99.6 % and PE likely in 0.4 % of total patients. D-dimer was obtained in only 37 % of patients who were unlikely to have a PE or had a low score on Wells’ criteria. Despite a low or unlikely Wells’ criteria score and normal d-dimer levels, 260 patients underwent imaging studies, and none were diagnosed with PE. Conclusion More than 99 % of CTPA or V/Q scans were negative in our study. This suggests extraordinary overutilisation of the imaging methods. D-dimer, recommended in patients with low to moderate risk, was ordered in only one-third of patients. Much greater emphasis of current guidelines is needed to avoid inappropriate utilisation of resources without missing diagnosis of PE.
- 21 January 2019
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 95 (1126) , 420-424
Overutilisation of imaging studies for diagnosis of pulmonary embolism: are we following the guidelines?
Objective To evaluate if imaging studies such as CT pulmonary angiography (CTPA) or ventilation–perfusion (V/Q) scan are ordered according to the current guidelines for the diagnosis of pulmonary embolism (PE). Methods We performed a retrospective observational cohort study in all adult patients who presented to the Sparrow Hospital Emergency Department from January 2014 to December 2016 and underwent CTPA or V/Q scan. We calculated the Wells’ score retrospectively, and d-dimer values were used to determine if the imaging study was justified. Results A total of 8449 patients underwent CTPA (93%) or V/Q scan (7%), among which 142 (0.2%) patients were diagnosed with PE. The Wells’ criteria showed low probabilities for PE in 96 % and intermediate or high probabilities in 4 % of total patients. Modified Wells’ criteria demonstrated PE unlikely in 99.6 % and PE likely in 0.4 % of total patients. D-dimer was obtained in only 37 % of patients who were unlikely to have a PE or had a low score on Wells’ criteria. Despite a low or unlikely Wells’ criteria score and normal d-dimer levels, 260 patients underwent imaging studies, and none were diagnosed with PE. Conclusion More than 99 % of CTPA or V/Q scans were negative in our study. This suggests extraordinary overutilisation of the imaging methods. D-dimer, recommended in patients with low to moderate risk, was ordered in only one-third of patients. Much greater emphasis of current guidelines is needed to avoid inappropriate utilisation of resources without missing diagnosis of PE.
- Open Access
- 2 October 2018
- Published by BMJ in BMJ Case Reports
- Vol. 2018
Spontaneous rupture of a pancreatic pseudocyst
- 2 October 2018
- Published by BMJ in BMJ Case Reports
- Vol. 2018
Open AccessSpontaneous rupture of a pancreatic pseudocyst